Stonepine Capital Management
Latest statistics and disclosures from Stonepine Capital Management's latest quarterly 13F-HR filing:
- Top 5 stock holdings are VSTM, ADMA, EOLS, NKTR, ZVRA, and represent 41.06% of Stonepine Capital Management's stock portfolio.
- Added to shares of these 10 stocks: IKT, CRBP, KZIA, VRCA, HELP, CRSP, ARE, ABEO, NKTR, ACET.
- Started 29 new stock positions in KTTA, ACET, ELDN, SPRB, CRIS, CGEN, MIST, RADX, CRBP, OVID.
- Reduced shares in these 10 stocks: DAWN, ENTA, SRZN, OABI, ZVRA, ACAD, BIOA, XFOR, SLNO, KZR.
- Sold out of its positions in WHWK, ABVX, GRCE, ACRS, ALMS, ANGO, AQST, ARDX, CMMB, CTMX. DVAX, HCAT, HSDT, JSPR, LRMR, Processa Pharmaceuticals, RZLT, SVRA, SLNO, SNDX, VNDA, VIR, ESTA.
- Stonepine Capital Management was a net buyer of stock by $6.6M.
- Stonepine Capital Management has $137M in assets under management (AUM), dropping by 11.35%.
- Central Index Key (CIK): 0001440771
Tip: Access up to 7 years of quarterly data
Positions held by Stonepine Capital Management consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Stonepine Capital Management
Stonepine Capital Management holds 64 positions in its portfolio as reported in the December 2025 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Verastem Com New (VSTM) | 15.4 | $21M | +2% | 2.7M | 7.72 |
|
| Adma Biologics (ADMA) | 9.9 | $14M | 740k | 18.24 |
|
|
| Evolus (EOLS) | 7.9 | $11M | +6% | 1.6M | 6.65 |
|
| Nektar Therapeutics Com New Call Option (NKTR) | 4.2 | $5.7M | +58% | 135k | 42.28 |
|
| Zevra Therapeutics Com New (ZVRA) | 3.7 | $5.1M | -29% | 569k | 8.96 |
|
| Inhibikase Therapeutics Com New (IKT) | 3.5 | $4.8M | +219% | 2.3M | 2.05 |
|
| Abeona Therapeutics Com New Call Option (ABEO) | 3.5 | $4.8M | +101% | 910k | 5.27 |
|
| Indivior Ord | 2.6 | $3.6M | 100k | 35.88 |
|
|
| Corbus Pharmaceuticals Hldgs Com New (CRBP) | 2.3 | $3.2M | NEW | 390k | 8.14 |
|
| Kazia Therapeutics Sponsored Ads (KZIA) | 2.3 | $3.2M | NEW | 460k | 6.89 |
|
| Xoma Royalty Corporation Com New (XOMA) | 2.2 | $3.1M | 115k | 26.59 |
|
|
| Verrica Pharmaceuticals Com Shs (VRCA) | 2.1 | $2.9M | NEW | 354k | 8.31 |
|
| Cybin Com New (HELP) | 2.0 | $2.8M | NEW | 340k | 8.18 |
|
| Tela Bio (TELA) | 2.0 | $2.8M | +9% | 2.4M | 1.18 |
|
| ACADIA Pharmaceuticals (ACAD) | 2.0 | $2.7M | -42% | 100k | 26.71 |
|
| Crispr Therapeutics Namen Akt Call Option (CRSP) | 1.9 | $2.6M | NEW | 50k | 52.44 |
|
| Surrozen Com New (SRZN) | 1.9 | $2.6M | -54% | 114k | 22.60 |
|
| Alexandria Real Estate Eq In Com New Call Option (ARE) | 1.8 | $2.4M | NEW | 50k | 48.94 |
|
| X4 Pharmaceuticals Com New (XFOR) | 1.7 | $2.4M | -43% | 594k | 4.00 |
|
| Ultragenyx Pharmaceutical Call Option (RARE) | 1.7 | $2.3M | +400% | 100k | 23.00 |
|
| Aytu Biopharma (AYTU) | 1.5 | $2.1M | -8% | 814k | 2.60 |
|
| Day One Biopharmaceuticals I (DAWN) | 1.4 | $1.9M | -69% | 200k | 9.32 |
|
| Adicet Bio Com New (ACET) | 1.4 | $1.9M | NEW | 220k | 8.42 |
|
| Spruce Biosciences Com New (SPRB) | 1.3 | $1.7M | NEW | 20k | 87.11 |
|
| Heron Therapeutics (HRTX) | 1.2 | $1.6M | +45% | 1.2M | 1.30 |
|
| Enanta Pharmaceuticals (ENTA) | 1.2 | $1.6M | -67% | 100k | 15.77 |
|
| Pmv Pharmaceuticals (PMVP) | 1.1 | $1.4M | -16% | 1.2M | 1.25 |
|
| Camp4 Therapeutics Corp (CAMP) | 1.0 | $1.4M | NEW | 229k | 6.13 |
|
| Eledon Pharmaceuticals (ELDN) | 1.0 | $1.3M | NEW | 893k | 1.51 |
|
| Milestone Pharmaceuticals (MIST) | 1.0 | $1.3M | NEW | 663k | 2.02 |
|
| Omniab (OABI) | 0.9 | $1.3M | -67% | 701k | 1.85 |
|
| Quoin Pharmaceuticals Sponsored Ads (QNRX) | 0.8 | $1.1M | NEW | 78k | 14.43 |
|
| Pulmonx Corp (LUNG) | 0.8 | $1.1M | -27% | 486k | 2.21 |
|
| Geron Corporation (GERN) | 0.8 | $1.1M | -49% | 806k | 1.32 |
|
| Crescent Biopharma (CBIO) | 0.8 | $1.0M | NEW | 88k | 11.86 |
|
| Kezar Life Sciences Com New (KZR) | 0.7 | $982k | -59% | 156k | 6.29 |
|
| Edesa Biotech Com New (EDSA) | 0.7 | $976k | 688k | 1.42 |
|
|
| Boundless Bio (BOLD) | 0.6 | $852k | +71% | 710k | 1.20 |
|
| Radiopharm Theranostics Sponsored Ads (RADX) | 0.6 | $852k | NEW | 51M | 0.02 |
|
| Semler Scientific | 0.6 | $765k | NEW | 50k | 15.29 |
|
| Maxcyte (MXCT) | 0.5 | $727k | +2% | 469k | 1.55 |
|
| An2 Therapeutics (ANTX) | 0.5 | $716k | +11% | 628k | 1.14 |
|
| Gossamer Bio (GOSS) | 0.5 | $635k | 205k | 3.10 |
|
|
| Zentalis Pharmaceuticals (ZNTL) | 0.5 | $626k | +2% | 464k | 1.35 |
|
| Bioage Labs (BIOA) | 0.4 | $595k | -76% | 45k | 13.23 |
|
| Mannkind Corp Com New (MNKD) | 0.4 | $490k | -45% | 86k | 5.67 |
|
| Compugen Ord (CGEN) | 0.3 | $467k | NEW | 305k | 1.53 |
|
| Codexis (CDXS) | 0.3 | $418k | +190% | 256k | 1.63 |
|
| In8bio Com New (INAB) | 0.3 | $386k | +3% | 165k | 2.34 |
|
| Fennec Pharmaceuticals (FENC) | 0.3 | $385k | NEW | 50k | 7.70 |
|
| Cabaletta Bio (CABA) | 0.3 | $375k | NEW | 171k | 2.19 |
|
| Pasithea Therapeutics Corp Com New (KTTA) | 0.3 | $355k | NEW | 275k | 1.29 |
|
| Pliant Therapeutics (PLRX) | 0.2 | $281k | -20% | 230k | 1.22 |
|
| Janux Therapeutics (JANX) | 0.2 | $276k | NEW | 20k | 13.80 |
|
| Delcath Sys Com New (DCTH) | 0.2 | $275k | NEW | 27k | 10.10 |
|
| Kiora Pharmaceuticals (KPRX) | 0.2 | $258k | -6% | 131k | 1.97 |
|
| CNS Pharmaceuticals (CNSP) | 0.2 | $256k | NEW | 49k | 5.25 |
|
| Tenaya Therapeutics (TNYA) | 0.2 | $250k | NEW | 352k | 0.71 |
|
| Ovid Therapeutics (OVID) | 0.1 | $167k | NEW | 102k | 1.63 |
|
| Tenax Therapeutics Com New (TENX) | 0.1 | $145k | NEW | 12k | 12.19 |
|
| Evaxion As Sponsored Ads (EVAX) | 0.1 | $95k | NEW | 20k | 4.77 |
|
| Xilio Therapeutics (XLO) | 0.1 | $81k | NEW | 126k | 0.64 |
|
| Curis (CRIS) | 0.0 | $59k | NEW | 59k | 0.99 |
|
| Processa Pharmaceuticals Com Shs (PCSA) | 0.0 | $36k | NEW | 12k | 2.88 |
|
Past Filings by Stonepine Capital Management
SEC 13F filings are viewable for Stonepine Capital Management going back to 2015
- Stonepine Capital Management 2025 Q4 filed Feb. 13, 2026
- Stonepine Capital Management 2025 Q3 filed Nov. 13, 2025
- Stonepine Capital Management 2025 Q2 filed Aug. 13, 2025
- Stonepine Capital Management 2025 Q1 filed May 14, 2025
- Stonepine Capital Management 2024 Q4 filed Feb. 14, 2025
- Stonepine Capital Management 2024 Q3 filed Nov. 13, 2024
- Stonepine Capital Management 2024 Q2 restated filed Aug. 21, 2024
- Stonepine Capital Management 2024 Q2 filed Aug. 13, 2024
- Stonepine Capital Management 2024 Q1 filed May 15, 2024
- Stonepine Capital Management 2023 Q4 filed Feb. 13, 2024
- Stonepine Capital Management 2023 Q3 filed Nov. 13, 2023
- Stonepine Capital Management 2023 Q2 amended filed Aug. 16, 2023
- Stonepine Capital Management 2023 Q2 filed Aug. 11, 2023
- Stonepine Capital Management 2023 Q1 filed May 12, 2023
- Stonepine Capital Management 2022 Q4 filed Feb. 14, 2023
- Stonepine Capital Management 2022 Q3 filed Nov. 10, 2022